Total Funding
20
30
Total FundingVenture - Series Unknown raised
Growth Score
0 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
72941
DescriptionIFM Therapeutics is a pharmaceutical company focused on developing biological treatments for autoimmune diseases.
Acquired by 
Bristol-Myers Squibb
- Gary Glick: Founder, CEO, and ChairmanPast Role: Scorpion Therapeutics, Co-Founder, Chief Executive Officer
Past Role: Schering-Plough, Director - U.S. Phase IV Studies
About the Company
IFM Therapeutics is a provider of small molecule that module novel targets in the innate immune system. The company and its academic collaborators combine unparalleled expertise in innate immunity with seasoned drug discovery and development professionals. Its subsidiary IFM Due is focused on the discovery and developing antagonists of the
cGAS/STING pathway for the treatment of inflammation, neuroinflammation, autoimmunity and cancer. IFM Discovery, a newly financed incubator entity within the IFM enterprise, is prosecuting a basket of genetically-validated targets as next-generation therapies for inflammation, neuroinflammation, autoimmunity and fibrosis
